3.84
price up icon7.87%   0.28
after-market Handel nachbörslich: 3.73 -0.11 -2.86%
loading
Schlusskurs vom Vortag:
$3.56
Offen:
$3.57
24-Stunden-Volumen:
67,379
Relative Volume:
0.78
Marktkapitalisierung:
$100.15M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.2471
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
+22.29%
1M Leistung:
+16.36%
6M Leistung:
-30.18%
1J Leistung:
+32.41%
1-Tages-Spanne:
Value
$3.30
$3.8844
1-Wochen-Bereich:
Value
$3.04
$3.8844
52-Wochen-Spanne:
Value
$1.5201
$16.94

Senti Biosciences Inc Stock (SNTI) Company Profile

Name
Firmenname
Senti Biosciences Inc
Name
Telefon
(650) 382-3281
Name
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Name
Mitarbeiter
48
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-16
Name
Neueste SEC-Einreichungen
Name
SNTI's Discussions on Twitter

Vergleichen Sie SNTI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SNTI
Senti Biosciences Inc
3.84 81.11M 1.79M -70.90M -34.95M -15.54
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.232 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.34 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 65.36B 14.09B 4.50B 2.96B 39.28

Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-10-07 Eingeleitet Morgan Stanley Equal-Weight

Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten

pulisher
09:05 AM

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - Yahoo Finance

09:05 AM
pulisher
05:16 AM

Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus

05:16 AM
pulisher
01:10 AM

Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com

01:10 AM
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
Jun 02, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 30, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 30, 2025
pulisher
May 29, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com

May 29, 2025
pulisher
May 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

May 27, 2025
pulisher
May 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

May 26, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire

May 26, 2025
pulisher
May 25, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 23, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times

May 23, 2025
pulisher
May 22, 2025

Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Senti Bio Cancer Therapy Achieves 71% Response Rate in AML Patients, Secures Additional $1M CIRM Grant - Stock Titan

May 22, 2025
pulisher
May 20, 2025

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com

May 20, 2025
pulisher
May 16, 2025

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 16, 2025
pulisher
May 09, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 08, 2025

Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com

May 08, 2025
pulisher
May 08, 2025

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World

May 07, 2025
pulisher
May 06, 2025

Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - Yahoo Finance

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent

May 05, 2025
pulisher
May 05, 2025

Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital - Defense World

May 05, 2025
pulisher
May 02, 2025

Senti Biosciences (SNTI) Maintains Buy Rating with Target Price Unchanged | SNTI Stock News - GuruFocus

May 02, 2025
pulisher
May 01, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

SNTI: Senti Bio Shares Positive Phase 1 Trial Results for SENTI-202 | SNTI Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Senti Bio Releases Virtual Investor "What This Means” Segment - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Senti Bio Releases Virtual Investor “What This Means” Segment - TradingView

May 01, 2025
pulisher
Apr 30, 2025

Senti Bio to Present at the Citizens JMP Life Sciences Conference - The Manila Times

Apr 30, 2025
pulisher
Apr 30, 2025

Breakthrough: Senti Bio's SENTI-202 Shows Promise in Treating Resistant Blood Cancer - Stock Titan

Apr 30, 2025
pulisher
Apr 29, 2025

Market Momentum Report: Prairie Operating Co (PROP)’s Positive Close at 4.10 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Closing Figures Unveiled: Senti Biosciences Inc (SNTI) Drop -27.20, Closes at 3.64 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

An Analysis of Senti Biosciences Inc (SNTI)’s Potential Price Growth - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025 - geneonline.com

Apr 29, 2025
pulisher
Apr 29, 2025

Senti Biosciences reports promising SENTI-202 trial results - Investing.com

Apr 29, 2025
pulisher
Apr 28, 2025

SNTI’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

SNTI’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 28, 2025

Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Senti Biosciences Inc-Aktie (SNTI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lu Timothy K
CEO
Feb 06 '25
Sale
4.36
545
2,376
82,082
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 04 '25
Sale
4.07
1,297
5,279
8,803
Rajangam Kanya
Pres. & Chief Med. & Dev. Off.
Feb 06 '25
Sale
4.37
182
795
8,621
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
Kapitalisierung:     |  Volumen (24h):